A new player is entering the metabolic disorder arena—and it’s oral. Innovent Biologics has received FDA approval to begin Phase 1 clinical trials for IBI3032, its in-house developed oral GLP-1 receptor agonist.
Why This Matters
GLP-1 receptor agonists are transforming treatment for:
- Type 2 diabetes
- Obesity
- Hypertension
- Obstructive sleep apnea (OSA)
Unlike injectable options, oral therapies offer:
- Easier administration
- Better patient compliance
- Potential for broader use in early interventions
Inside IBI3032: A Targeted Metabolic Approach
IBI3032 is a small-molecule GLP-1 receptor agonist, designed using structure-based drug discovery and optimized for oral delivery.
Mechanism of Action
- Activates GLP-1 receptors
- Slows gastric emptying
- Reduces appetite
- Boosts insulin secretion via the cAMP pathway
Preclinical Highlights
- Higher oral bioavailability vs. other GLP-1 analogs
- Strong efficacy in animal models
- Favorable safety and pharmacokinetic profile
What’s Next: Dual Trials in US and China
Phase 1 trials will begin in the second half of 2025. Participants will include:
- Healthy volunteers
- Overweight and obese individuals
Both the FDA and China’s NMPA have approved the study—marking global regulatory support for Innovent’s pipeline.
Part of a Bigger Vision
This program complements Innovent’s broader cardiovascular and metabolic (CVM) strategy, where mazdutide remains a core asset.
With IBI3032 entering clinical trials, Innovent signals its ambition to compete globally in oral metabolic therapeutics.
